Chi D S, Liao J B, Leon L F, Venkatraman E S, Hensley M L, Bhaskaran D, Hoskins W J
Gynecology Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Gynecol Oncol. 2001 Sep;82(3):532-7. doi: 10.1006/gyno.2001.6328.
The Gynecologic Oncology Group (GOG) has demonstrated that age, tumor grade, and size and number of residual lesions after primary cytoreductive surgery are significant prognostic factors in advanced ovarian carcinoma. Recent studies have reported numerous other clinical features as having prognostic value. We sought to identify the independent prognostic factors for survival in a cohort of patients with advanced ovarian cancer.
We performed a retrospective chart review of all patients with stage III and IV ovarian carcinoma who received their primary treatment at our institution between 1987 and 1994.
A total of 295 patients were identified, 282 of whom were evaluable. Of these 282 patients, 214 (76%) have died of disease or other causes. The median follow-up is 32 months (range: 1-139). Eighteen factors were evaluated for prognostic significance. Significant factors in univariate analysis included patient age, gravidity (0 vs > 0), parity (0 vs > 0), preoperative albumin level, preoperative total protein level, ascites (presence vs absence), disease stage (IIIA/IIIB vs IIIC vs IV), number of residual lesions (< or =20 vs >20), and diameter of largest residual tumor nodule (< or = 1 cm vs 1-2 cm vs > 2 cm). However, on multivariate analysis, only patient age (P < 0.001), ascites (P = 0.001), and size of residual disease (P = 0.005) retained prognostic significance. Substage of disease was of borderline significance (P = 0.086).
Although numerous clinical variables have recently been reported to have prognostic value in advanced ovarian carcinoma, only patient age, presence or absence of ascites, and diameter of the largest residual tumor nodule proved to be of statistical significance in our analysis.
妇科肿瘤学组(GOG)已证实,年龄、肿瘤分级、初次肿瘤细胞减灭术后残留病灶的大小和数量是晚期卵巢癌的重要预后因素。近期研究报道了许多其他具有预后价值的临床特征。我们试图确定晚期卵巢癌患者队列中生存的独立预后因素。
我们对1987年至1994年间在本机构接受初次治疗的所有III期和IV期卵巢癌患者进行了回顾性病历审查。
共确定了295例患者,其中282例可评估。在这282例患者中,214例(76%)死于疾病或其他原因。中位随访时间为32个月(范围:1 - 139个月)。对18个因素进行了预后意义评估。单因素分析中的显著因素包括患者年龄、妊娠次数(0次与>0次)、产次(0次与>0次)、术前白蛋白水平、术前总蛋白水平、腹水(存在与不存在)、疾病分期(IIIA/IIIB期与IIIC期与IV期)、残留病灶数量(≤20个与>20个)以及最大残留肿瘤结节直径(≤1 cm与1 - 2 cm与>2 cm)。然而,多因素分析显示,只有患者年龄(P < 0.001)、腹水(P = 0.001)和残留病灶大小(P = 0.005)保留了预后意义。疾病亚分期具有临界显著性(P = 0.086)。
尽管近期有许多临床变量被报道在晚期卵巢癌中具有预后价值,但在我们的分析中,只有患者年龄、腹水的有无以及最大残留肿瘤结节的直径具有统计学意义。